Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Primary Central Nervous System Lymphoma · Recurrent Cancer · Refractory Cancer · Relapsed Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Christian Grommes, MD)
Study leads
Lakshmi Nayak, MD
Principal Investigator
Dana-Farber Cancer Institute